Table 1 Summary of study cases

LGSC-2

UHN

57

2

IIIC

2-P*

Carboplatin/paclitaxel

2-R (46 mo)

86 mo / AWD

LGSC-3

UHN

51

2

IIIC

3-P*

Carboplatin/paclitaxel

3-R (17 mo)

19 mo / AWD

LGSC-4

UHN

66

3

IIIB

4-P

Carboplatin

4-R1 (25 mo), 4-R2 (45 mo)

60 mo / DOD

LGSC-5

MDACC

51

2

IIIC

5-P

Carboplatin/paclitaxel, letrozole

5-R (37 mo)

53 mo / DOD

LGSC-6

MDACC

41

2

IIIC

6-P

Carboplatin/paclitaxel

6-R (24 mo)

87 mo / DOD

LGSC-8

MDACC

33

2

IIIC

8-P

Cisplatin/cyclophos-phamide

8-R (7 mo)

12 mo / DOD

LGSC-9**

BCCA

51

6

IIIB

9-P1, P2, P3*

No treatment

9-R1, R2, R3 (100 mo)

141 mo / DOD

LGSC-10

BCCA

57

8

IV

10-P1, P2, P3, P4*

Carboplatin/paclitaxel, radiation

10-R1, R2, R3, R4 (45 mo)

62 mo / DOD

LGSC-11**

BCCA

62

2

IIIC

11-P*

No treatment

11-R (156 mo)

180 mo / DOD

LGSC-12

BCCA

57

6

IIB

12-P1, P2, P3, P4*

Etoposide, tamoxifen, anastrozole

12-R1, R2 (18 mo)

53 mo / DOD

LGSC-13

BCCA

58

2

IIIB

13-P*

Carboplatin/paclitaxel

13-R (46 mo)

59 mo / DOD

Mean (Total)

53.1

3.4 (37)